Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Nov 15;100(10):2596–2605. doi: 10.1172/JCI119803

Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture.

Y Imai 1, W H Busby Jr 1, C E Smith 1, J B Clarke 1, A J Garmong 1, G D Horwitz 1, C Rees 1, D R Clemmons 1
PMCID: PMC508461  PMID: 9366575

Abstract

IGFs are pleiotrophic mitogens for porcine smooth muscle cells (pSMC) in culture. The effects of IGFs on cells are modulated by various insulin-like growth factor-binding proteins (IGFBP). IGFBP-5 is synthesized by pSMC and binds to the extracellular matrix. However, IGFBP-5 is also secreted into conditioned medium of cultured cells and is cleaved into fragments by a concomitantly produced protease. These fragments have reduced affinity for the IGFs and cleavage makes it difficult to assess the role of intact IGFBP-5. To study the consequence of accumulation of intact IGFBP-5 in medium, we determined the cleavage site in IGFBP-5 and prepared a protease resistant mutant. Amino acid sequencing of purified IGFBP-5 fragments suggested Arg138-Arg139 as the primary cleavage site. Arg138-Arg139-->Asn138-Asn139 mutations were introduced to create protease-resistant IGFBP-5, which has the same affinity for IGF-I as the native protein. This mutant IGFBP-5 remained intact even after 24 h of incubation and it inhibited several IGF-I actions when added to pSMC culture medium. The mutant IGFBP-5 (500 ng/ml) decreased IGF-I stimulated cellular DNA synthesis by 84%, protein synthesis by 77%, and it inhibited IGF-I stimulated migration of pSMC by 77%. It also inhibited IGF-I stimulation of IRS-1 phosphorylation. In contrast, the same amount of native IGFBP-5 did not inhibit IGF-I actions. The significance of inhibitory effects of the protease resistant IGFBP-5 was further demonstrated in pSMC transfected with mutant or native IGFBP-5 cDNAs. The mutant IGFBP-5 accumulated in culture medium of transfected cells, while native IGFBP-5 was degraded into fragments, PSMC overexpressing the mutant IGFBP-5 also responded poorly to IGF-I compared with mock transfected cells. IGF-I (5 ng/ml) increased [35S]methionine incorporation into control cells by 36% above the basal level, but it did not significantly change (4%) in pSMC cultures that were producing the mutant IGFBP-5. In conclusion, the accumulation of protease-resistant IGFBP-5 in the medium was inhibitory to IGF-I actions on pSMC. This suggests that proteolysis can prevent IGFBP-5 from acting as an inhibitor of IGF-I-stimulated effects and that it serves as an important mechanism for regulating cellular responsiveness to IGF-I.

Full Text

The Full Text of this article is available as a PDF (276.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andress D. L., Birnbaum R. S. Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J Biol Chem. 1992 Nov 5;267(31):22467–22472. [PubMed] [Google Scholar]
  2. Arai T., Arai A., Busby W. H., Jr, Clemmons D. R. Glycosaminoglycans inhibit degradation of insulin-like growth factor-binding protein-5. Endocrinology. 1994 Dec;135(6):2358–2363. doi: 10.1210/endo.135.6.7527332. [DOI] [PubMed] [Google Scholar]
  3. Arai T., Busby W., Jr, Clemmons D. R. Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology. 1996 Nov;137(11):4571–4575. doi: 10.1210/endo.137.11.8895319. [DOI] [PubMed] [Google Scholar]
  4. Arai T., Clarke J., Parker A., Busby W., Jr, Nam T., Clemmons D. R. Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin. J Biol Chem. 1996 Mar 15;271(11):6099–6106. doi: 10.1074/jbc.271.11.6099. [DOI] [PubMed] [Google Scholar]
  5. Bautista C. M., Baylink D. J., Mohan S. Isolation of a novel insulin-like growth factor (IGF) binding protein from human bone: a potential candidate for fixing IGF-II in human bone. Biochem Biophys Res Commun. 1991 Apr 30;176(2):756–763. doi: 10.1016/s0006-291x(05)80249-9. [DOI] [PubMed] [Google Scholar]
  6. Bornfeldt K. E., Arnqvist H. J., Capron L. In vivo proliferation of rat vascular smooth muscle in relation to diabetes mellitus insulin-like growth factor I and insulin. Diabetologia. 1992 Feb;35(2):104–108. doi: 10.1007/BF00402540. [DOI] [PubMed] [Google Scholar]
  7. Bornfeldt K. E., Raines E. W., Nakano T., Graves L. M., Krebs E. G., Ross R. Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest. 1994 Mar;93(3):1266–1274. doi: 10.1172/JCI117081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bourner M. J., Busby W. H., Jr, Siegel N. R., Krivi G. G., McCusker R. H., Clemmons D. R. Cloning and sequence determination of bovine insulin-like growth factor binding protein-2 (IGFBP-2): comparison of its structural and functional properties with IGFBP-1. J Cell Biochem. 1992 Feb;48(2):215–226. doi: 10.1002/jcb.240480212. [DOI] [PubMed] [Google Scholar]
  9. Busby W. H., Jr, Klapper D. G., Clemmons D. R. Purification of a 31,000-dalton insulin-like growth factor binding protein from human amniotic fluid. Isolation of two forms with different biologic actions. J Biol Chem. 1988 Oct 5;263(28):14203–14210. [PubMed] [Google Scholar]
  10. Camacho-Hubner C., Busby W. H., Jr, McCusker R. H., Wright G., Clemmons D. R. Identification of the forms of insulin-like growth factor-binding proteins produced by human fibroblasts and the mechanisms that regulate their secretion. J Biol Chem. 1992 Jun 15;267(17):11949–11956. [PubMed] [Google Scholar]
  11. Carmeliet P., Moons L., Ploplis V., Plow E., Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest. 1997 Jan 15;99(2):200–208. doi: 10.1172/JCI119148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Clemmons D. R. Exposure to platelet-derived growth factor modulates the porcine aortic smooth muscle cell response to somatomedin-C. Endocrinology. 1985 Jul;117(1):77–83. doi: 10.1210/endo-117-1-77. [DOI] [PubMed] [Google Scholar]
  13. Clemmons D. R., Shaw D. S. Variables controlling somatomedin production by cultured human fibroblasts. J Cell Physiol. 1983 May;115(2):137–142. doi: 10.1002/jcp.1041150206. [DOI] [PubMed] [Google Scholar]
  14. Clemmons D. R., Van Wyk J. J. Evidence for a functional role of endogenously produced somatomedinlike peptides in the regulation of DNA synthesis in cultured human fibroblasts and porcine smooth muscle cells. J Clin Invest. 1985 Jun;75(6):1914–1918. doi: 10.1172/JCI111906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Clowes A. W., Clowes M. M., Au Y. P., Reidy M. A., Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res. 1990 Jul;67(1):61–67. doi: 10.1161/01.res.67.1.61. [DOI] [PubMed] [Google Scholar]
  16. Cohick W. S., Gockerman A., Clemmons D. R. Vascular smooth muscle cells synthesize two forms of insulin-like growth factor binding proteins which are regulated differently by the insulin-like growth factors. J Cell Physiol. 1993 Oct;157(1):52–60. doi: 10.1002/jcp.1041570107. [DOI] [PubMed] [Google Scholar]
  17. Conover C. A., Kiefer M. C. Regulation and biological effect of endogenous insulin-like growth factor binding protein-5 in human osteoblastic cells. J Clin Endocrinol Metab. 1993 May;76(5):1153–1159. doi: 10.1210/jcem.76.5.7684391. [DOI] [PubMed] [Google Scholar]
  18. Culouscou J. M., Shoyab M. Purification of a colon cancer cell growth inhibitor and its identification as an insulin-like growth factor binding protein. Cancer Res. 1991 Jun 1;51(11):2813–2819. [PubMed] [Google Scholar]
  19. De Mellow J. S., Baxter R. C. Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts. Biochem Biophys Res Commun. 1988 Oct 14;156(1):199–204. doi: 10.1016/s0006-291x(88)80824-6. [DOI] [PubMed] [Google Scholar]
  20. Delafontaine P., Anwar A., Lou H., Ku L. G-protein coupled and tyrosine kinase receptors: evidence that activation of the insulin-like growth factor I receptor is required for thrombin-induced mitogenesis of rat aortic smooth muscle cells. J Clin Invest. 1996 Jan 1;97(1):139–145. doi: 10.1172/JCI118381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Delafontaine P., Lou H., Alexander R. W. Regulation of insulin-like growth factor I messenger RNA levels in vascular smooth muscle cells. Hypertension. 1991 Dec;18(6):742–747. doi: 10.1161/01.hyp.18.6.742. [DOI] [PubMed] [Google Scholar]
  22. Duan C., Hawes S. B., Prevette T., Clemmons D. R. Insulin-like growth factor-I (IGF-I) regulates IGF-binding protein-5 synthesis through transcriptional activation of the gene in aortic smooth muscle cells. J Biol Chem. 1996 Feb 23;271(8):4280–4288. doi: 10.1074/jbc.271.8.4280. [DOI] [PubMed] [Google Scholar]
  23. Gockerman A., Prevette T., Jones J. I., Clemmons D. R. Insulin-like growth factor (IGF)-binding proteins inhibit the smooth muscle cell migration responses to IGF-I and IGF-II. Endocrinology. 1995 Oct;136(10):4168–4173. doi: 10.1210/endo.136.10.7545099. [DOI] [PubMed] [Google Scholar]
  24. Hunkapiller M. W., Hewick R. M., Dreyer W. J., Hood L. E. High-sensitivity sequencing with a gas-phase sequenator. Methods Enzymol. 1983;91:399–413. doi: 10.1016/s0076-6879(83)91038-8. [DOI] [PubMed] [Google Scholar]
  25. Jones J. I., Gockerman A., Busby W. H., Jr, Camacho-Hubner C., Clemmons D. R. Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol. 1993 May;121(3):679–687. doi: 10.1083/jcb.121.3.679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Khorsandi M. J., Fagin J. A., Giannella-Neto D., Forrester J. S., Cercek B. Regulation of insulin-like growth factor-I and its receptor in rat aorta after balloon denudation. Evidence for local bioactivity. J Clin Invest. 1992 Nov;90(5):1926–1931. doi: 10.1172/JCI116070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. King G. L., Goodman A. D., Buzney S., Moses A., Kahn C. R. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest. 1985 Mar;75(3):1028–1036. doi: 10.1172/JCI111764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Mohan S., Bautista C. M., Wergedal J., Baylink D. J. Isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell-conditioned medium: a potential local regulator of IGF action. Proc Natl Acad Sci U S A. 1989 Nov;86(21):8338–8342. doi: 10.1073/pnas.86.21.8338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Nam T. J., Busby W. H., Jr, Clemmons D. R. Human fibroblasts secrete a serine protease that cleaves insulin-like growth factor-binding protein-5. Endocrinology. 1994 Oct;135(4):1385–1391. doi: 10.1210/endo.135.4.7523096. [DOI] [PubMed] [Google Scholar]
  30. Parker A., Gockerman A., Busby W. H., Clemmons D. R. Properties of an insulin-like growth factor-binding protein-4 protease that is secreted by smooth muscle cells. Endocrinology. 1995 Jun;136(6):2470–2476. doi: 10.1210/endo.136.6.7538463. [DOI] [PubMed] [Google Scholar]
  31. Reeve J. G., Schwander J., Bleehen N. M. IGFBP-2: an important regulator of insulin-like growth factor action in human lung tumours? Growth Regul. 1993 Mar;3(1):82–84. [PubMed] [Google Scholar]
  32. Ross M., Francis G. L., Szabo L., Wallace J. C., Ballard F. J. Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. Biochem J. 1989 Feb 15;258(1):267–272. doi: 10.1042/bj2580267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ross R. The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol. 1971 Jul;50(1):172–186. doi: 10.1083/jcb.50.1.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Schmid C., Rutishauser J., Schläpfer I., Froesch E. R., Zapf J. Intact but not truncated insulin-like growth factor binding protein-3 (IGFBP-3) blocks IGF I-induced stimulation of osteoblasts: control of IGF signalling to bone cells by IGFBP-3-specific proteolysis? Biochem Biophys Res Commun. 1991 Aug 30;179(1):579–585. doi: 10.1016/0006-291x(91)91410-e. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES